logo

For the Inventor, By the Inventor

Lund, Sweden

Peter Hansen

This inventor holds 10 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: Astrazeneca Ab. Active years: 2005-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Hansen. Retrieved from https://idiyas.com/inventor/peter-hansen-7v94pxe9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 10.0

 

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 41(Granted Patents)


Location History:

  • Staffanstorp, SE (2005)
  • Lund, SE (2011 - 2013)

Company Filing History:

goldMedal10 out of 1,531 
 
Astrazeneca Ab
 patents

Years Active: 2005-2013

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 8501784 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use (2013-08-06),
2. 8410114 - 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial (2013-04-02),
3. 8338587 - Compounds (2012-12-25),
4. 8163724 - Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (2012-04-24),
5. 8114881 - 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial (2012-02-14),
6. 8063073 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use (2011-11-22),
7. 7998984 - 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial (2011-08-16),
8. 6951874 - Compounds (2005-10-04),
9. 6943188 - Hydroxyalkyl compounds (2005-09-13),
10. 6927222 - Compounds (2005-08-09),

Title: Innovations of Peter Hansen

Introduction

Peter Hansen is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit neutrophil elastase. With a total of 10 patents to his name, Hansen's work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Hansen's latest patents include innovative compounds such as 2-pyridone derivatives and 2-pyrazinone derivatives. The 2-pyridone derivatives serve as neutrophil elastase inhibitors, providing novel compounds with specific formulas and their respective optical isomers, racemates, and tautomers. These compounds are designed for therapeutic use, showcasing their potential in treating conditions related to neutrophil elastase activity. Similarly, the 2-pyrazinone derivatives are aimed at treating diseases where inhibiting neutrophil elastase is beneficial, further emphasizing Hansen's focus on this critical area of research.

Career Highlights

Peter Hansen is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry. Hansen's expertise and innovative mindset have positioned him as a key player in the field.

Collaborations

Hansen has collaborated with talented individuals such as Karolina Lawitz and Antonios Nikitidis. These collaborations have fostered a productive environment for innovation and have led to the advancement of their shared research goals.

Conclusion

Peter Hansen's contributions to the field of pharmaceutical sciences through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new therapeutic options in the treatment of diseases related to neutrophil elastase.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…